W2O handles media for MyoKardia as the clinical biopharmaceutical firm agrees to be acquired by Bristol-Myers-Squibb for $13.1B in cash, which represents a 60 percent premium over the California-based company’s Oct. 2 closing stock price.
BMS CEO Giovanni Caforio said MyKardia’s mavacamten cardiovascular drug was a key reason for the deal.
He called mavacamten, “a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease.”
Mavacamten treats obstructive hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes too thick.
There are 160K to 200K people in the US and EU diagnosed with HCM, which has no effective treatment. It’s estimated that only 25 percent of people with HCM receive a diagnosis.
MyoKardia expects to file a new drug application for mavacamten with the Food & Drug Administration during the first quarter of 2021.
W2O’s Julie Nomert handles MyoKardia, while Hannah Deresiewicz of Stern Investor Relations handles Wall Street.
No comments have been submitted for this story yet.